Somaxon Slaps Par With 2nd Suit Over Generic Silenor

Law360, New York (May 27, 2011, 9:06 PM EDT) -- Somaxon Pharmaceuticals Inc. hit Par Pharmaceutical Cos. Inc. with a patent infringement suit in Delaware on Thursday, seeking to prevent the release of the generic drug maker's version of Somaxon's prescription insomnia medication Silenor.

Par had informed Somaxon in a letter on May 10 that it was submitting an abbreviated new drug application to the U.S. Food and Drug Administration to get the agency's approval to make and sell 3-milligram and 6-milligram dosages of generic doxepin hydrochloride tablets, which have the same active ingredients and dosage...
To view the full article, register now.